ArticleScientific reports2026
Machine learning-based prediction of progression from idiopathic cytopenia of undetermined significance to myeloid malignancies.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Although the risk of progression varies, a subset of patients with idiopathic cytopenia of undetermined significance (ICUS) eventually develop myeloid malignancies. Early identification of high-risk patients is crucial for timely intervention and optimized clinical management. This study aimed to develop a machine learning-based model to predict the progression of ICUS to myeloid malignancies. We retrospectively analyzed data from 1274 patients who underwent bone marrow examination at Asan Medical Center, Seoul, South Korea, between January 2000 and December 2021 and met the diagnostic criteria for ICUS. Among these patients, 36 (2.82%) progressed to myeloid malignancies. We developed a predictive model using the extreme gradient boosting algorithm, incorporating clinical, laboratory, and cytogenetic features. The model achieved an area under the receiver operating characteristic curve of 0.780, with enhanced performance after integrating PubMedBERT to extract insights from unstructured text data from bone marrow examination reports. Additionally, we applied SHapley Additive exPlanations to generate individualized risk scores, estimate progression probabilities, and visualize key predictive features, enabling personalized risk assessment. In conclusion, we developed a machine learning-based model predicting ICUS progression to myeloid malignancies. This model could serve as a valuable tool for personalized risk stratification and tailored patient monitoring in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.